« Return to News | Drug Sponsors | CROs/Service Providers

Ark Therapeutics signs a letter of intent with EMD Millipore

Friday, August 17, 2012 11:13 AM

Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. 

Key elements of the collaboration focus on production optimization of viral based bioengineered vaccines and other live viral products for pilot and production scale and the installation of these processes at Ark's GMP manufacturing facility in Kuopio, Finland. Additionally, the parties plan to establish a GMP BSL-2 suite in the Kuopio facility equipped with EMD Millipore process technology to enable Ark's wider routine use of EMD Millipore process technology in its manufacturing services business.  

The collaboration “combines Ark's unrivalled expertise in commercial sable GMP manufacturing processes for live viral products and EMD Millipore's pre-eminent position in bioprocessing integrated solutions and high-performance devices,” said Dr. David Venables, CEO of Ark.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.